A comprehensive view of Merck KGaA. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Merck KGaA hands over IL-12-targeting cancer drug to PDS Biotech in deal worth over US$120.0M; the two companies are currently developing a triple combination immunotherapy to treat HPV-associated malignancies

Amgen, Merck KGaA sign separate deals to develop cancer-targeting antibody-drug conjugates with external drug developers in deals worth up to US$2.0B; Amgen partners with LegoChem Biosciences, Merck partners with Mersana Therapeutics

CEOs of BioNTech, Bayer, Merck KGaA join German Chancellor Scholz in high-profile China visit

Merck KGaA plans to double R&D productivity, introduce one new product or major indication every 1.5 years on average; over 50% of new launches to result from external co-development partnerships and strategic in-licensing of assets

AstraZeneca and MSD's Lynparza combined with abiraterone and prednisone or prednisolone has been recommended in the EU for approval as a treatment for metastatic castration-resistant prostate cancer

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count